Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies
Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies
复制标题
诊断主要药物研究实验室的衰落：制药公司的处方
DOI：
10.1002/ddr.430340302
复制
发表时间：
1995
影响因子：
3.8
通讯作者：
W. Moos
中科院分区：
文献类型：
--
作者：
J. Weisbach;W. Moos
尽管大型制药公司的内部药物研发（R&D）支出大幅增加，但内部发现的突破性产品很少。相比之下，生物技术公司在产生有前途的生物医学候选产品方面发挥着越来越重要的作用，而且私人资金要少得多。从财务、管理到科学的各种因素来看，我们认为，20世纪世纪包含了主要药物发现研究实验室的兴起和衰落。在这里，我们提供了一个简明的背景，该行业及其目前的困境。在诊断了现有组织固有的一些问题之后，我们提供了一个改变的处方，它将制药公司置于与生物技术企业联盟的中心。我们认为，用同样或更少的资金，制药公司可以显著提高现有的研究生产力，风险更小，回报可能更高。如果这种方法被广泛和成功地采用，对病人、医疗保健行业、许多大公司、他们的员工和股东以及整个经济的影响可能是“医生所要求的”！这些经验教训和建议也可能对其他以研究为基础的行业有价值。© 1995 Wiley利斯公司
Despite dramatically increasing expenditures for in‐house pharmaceutical research and development (R&D) at major drug companies, few internally discovered, breakthrough products are on the horizon. In contrast, and for significantly less private funding, biotechnology companies are playing an ever more significant role in generating promising biomedical product candidates. For a variety of factors, ranging from financial and management to scientific in nature, we suggest that the twentieth century has encompassed the rise and decline of major pharmaceutical discovery research laboratories. Herein, we provide a concise background to the industry and its current predicament. Having diagnosed some of the problems inherent to the existing organizations, we provide a prescription for change, which places pharmaceutical companies at the center of constellations of alliances with biotech ventures. We posit that, for the same or even fewer dollars, pharmaceutical companies could significantly enhance existing research productivity, with less risk, and with potentially higher rewards. Where this approach to be adopted broadly and successfully, the effect on patients, the healthcare industry, numerous major corporations, their employees and stockholders, and the economy in general, could be “just what the doctor ordered”! These lessons and proposals may also have merit in other research‐based industries. © 1995 Wiley‐Liss, Inc.